


A New Synthetic Approach to the Carbapenem Antibiotic PS-5  
from Ethyl (S)-3-Hydroxybutanoate

Toshiyuki CHIBA<sup>†</sup> and Takeshi NAKAI\*

Department of Chemical Technology,  
Tokyo Institute of Technology, Meguro-ku, Tokyo 152


A new synthetic route to the PS-5 key precursor is described which involves the fully stereocontrolled transformation of the optically active 2-azetidinone derivative easily obtainable from ethyl (S)-3-hydroxybutanoate.

The carbapenem antibiotic (+)-PS-5 (1)<sup>1)</sup> has currently been the focus of considerable synthetic activities.<sup>2)</sup> In an effort to develop new synthetic routes to carbapenem antibiotics from (R)- or (S)-3-hydroxybutanoic esters (2)<sup>3)</sup> which are commercially available in large quantity, we have recently reported that the enolate-imine condensation of (S)-2 with the silylimine generated in situ from trimethylsilylpropynal affords the 2-azetidinone derivative (+)-3 as a major product.<sup>4)</sup> We now wish to report a facile scheme for the stereocontrolled transformation of (+)-3 to a PS-5 key precursor.



The following scheme depicts the newly-developed sequence starting with (+)-3 prepared from (S)-2 of ca. 80% ee.<sup>5)</sup> First, the hydroxy group on the side chain was removed by bromination followed by reduction with zinc to give the 3-ethyl derivative (4);<sup>6)</sup>  $[\alpha]_D^{20} -41.1^\circ$  ( $c$  1.08,  $\text{CHCl}_3$ ), which was then subjected to the hydration/Baeyer-Villiger sequence<sup>7)</sup> to afford the 4-acetoxy derivative (5)<sup>6)</sup> with 3,4-cis configuration ( $J_{3,4}=4.2$  Hz);  $[\alpha]_D^{22} -113.9^\circ$  ( $c$  0.99,  $\text{CHCl}_3$ ). The reaction of 5 with the silyl enol ether (6), prepared by the reported method,<sup>2a)</sup> proceeded with complete inversion of configuration at C-4 to give the 3,4-trans adduct (7);<sup>6)</sup>  $[\alpha]_D^{17} +47.8^\circ$  ( $c$  0.60,  $\text{CHCl}_3$ ).<sup>8)</sup> The thermal cyclization of 7 carried out according to the reported procedure<sup>9)</sup> gave rise to the desired PS-5 precursor (8), of which the IR and NMR data are in accord with the reported values.<sup>2a)</sup> Since the precursor 8 has already been converted to (+)-PS-5,<sup>2)</sup> we have now completed the formal synthesis of (+)-PS-5 from the easily available (S)-3-hydroxybutanoic ester.

<sup>†</sup> Visiting Research Fellow from Fujisawa Pharmaceutical Co., Ltd., Osaka.



a:  $\text{CBr}_4/\text{PPh}_3$ , THF; b:  $\text{Zn}/\text{HCO}_2\text{H}$ , *N,N*-Dimethylformamide; c:  $\text{H}_2\text{SO}_4/\text{HgSO}_4$ , aq. THF; d: *m*-Chloroperbenzoic acid, AcOEt; e:  $\text{CH}_2=\text{C}(\text{OSiMe}_3)-\text{CN}_2-\text{CO}_2\text{PNB}$  (6)/ $\text{Me}_3\text{SiOSO}_2\text{CF}_3$ ,  $\text{CH}_2\text{Cl}_2$ ; f: Reflux in hexane in the presence of  $\text{Rh}_2(\text{OCOC}_7\text{H}_{15}\text{-n})_4$

In summary, we have now developed a new synthetic route to the optically active PS-5 key precursor from the inexpensive chiral starting material. Further improvement of the present approach is now in progress.

The authors are grateful to Dr. Takao Takaya for his helpful discussion.

#### References

- 1) Isolation: K. Yamamoto, T. Yoshioka, Y. Kato, M. Shibamoto, K. Okamura, Y. Shimauchi, and T. Ishikura, *J. Antibiot.*, **33**, 796 (1980).
- 2) Recent syntheses of (+)- and (±)-PS-5: a) T. Kametani, T. Honda, A. Nakayama, Y. Sasaki, T. Mochizuki, and K. Fukumoto, *J. Chem. Soc., Perkin Trans. 1*, **1981**, 2228; b) D. Favara, A. Omedei-Salè, P. Consonni, and A. Depaoli, *Tetrahedron Lett.*, **23**, 3105 (1982); c) C.-N. Hsiao, S. P. Ashburn, and M. J. Miller, *ibid.*, **26**, 4855 (1985); d) D. Hart, C.-S. Lee, W. H. Pirkle, M. H. Hyon, and A. Tsipouras, *J. Am. Chem. Soc.*, **108**, 6054 (1986); e) D. A. Evans and E. B. Sjogren, *Tetrahedron Lett.*, **27**, 3119 (1986); f) N. Yamazaki, M. Murakami, and T. Mukaiyama, *Chem. Lett.*, **1986**, 1013.
- 3) Review: T. Nakai and T. Chiba, *Farumashia*, **22**, 611 (1986). For the synthetic route to the thienamycin key precursor from (*R*)-2, see: T. Chiba and T. Nakai, *Tetrahedron Lett.*, **26**, 4647 (1985), and references cited therein.
- 4) T. Chiba, M. Nagatsuma, and T. Nakai, *Chem. Lett.*, **1985**, 1343.
- 5) The yield of each step has not been optimized yet.
- 6) The IR and  $^1\text{H}$  NMR spectral data of these intermediates are in accord with the reported values<sup>2a,b)</sup> and/or the assigned structures.
- 7) T. Chiba and T. Nakai, *Chem. Lett.*, **1985**, 651.
- 8) Lit.<sup>2b)</sup>  $[\alpha]_D^{22} +64.7^\circ$  ( $c$  1.0,  $\text{CHCl}_3$ );  $J_{3,4} = 2.0$  Hz.
- 9) T. Salzmann, R. W. Rarcliff, and B. G. Christensen, *Tetrahedron Lett.*, **21**, 31 (1980)

(Received August 12, 1987)